Focused On-demand Library for 5-hydroxytryptamine receptor 1F

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P30939

UPID:

5HT1F_HUMAN

Alternative names:

Serotonin receptor 1F

Alternative UPACC:

P30939

Background:

The 5-hydroxytryptamine receptor 1F, also known as the Serotonin receptor 1F, plays a pivotal role in neurotransmission and neuromodulation. This receptor is a G-protein coupled receptor (GPCR) that binds to serotonin, a key neurotransmitter involved in regulating mood, appetite, and sleep. Activation of this receptor leads to a conformational change, initiating signaling pathways that ultimately inhibit adenylate cyclase activity, thereby modulating cellular responses.

Therapeutic significance:

Understanding the role of 5-hydroxytryptamine receptor 1F could open doors to potential therapeutic strategies. Its involvement in serotonin signaling makes it a potential target for treating disorders related to mood, appetite, and sleep regulation.